Results 91 to 100 of about 1,664 (165)

Factors associated with hematological adverse reactions of drugs authorized via the centralized procedure

Scientific Reports
Serious hematological adverse drug reactions (HADRs) may lead to or prolong hospitalization and even cause death. The aim of this study was to determine the regulatory factors associated with HADRs caused by drugs that were authorized up to July 2023 by ...
Ivana Stević, Slobodan M. Janković, Andrijana Milošević Georgiev, Valentina Marinković, Dragana Lakić   +4 more
doaj   +1 more source

Intentional Somatropin Exposure Reported to United States Poison Control from 2013-2023

Retrospective National Poison Data System review of intentional somatropin exposures reported to U.S. poison control centers from 2013 to 2023. The project describes exposure reasons, demographics, chronicity, co-ingestants, clinical outcomes, and the ...
Annalise Parks; Amberly Johnson
core  

Unintentional Somatropin Exposures Reported to US Poison Control Centers from 2013-2023

Retrospective National Poison Data System review of unintentional somatropin exposures reported to U.S. poison control centers from 2013 to 2023. The study describes exposure reasons, demographics, medical outcomes, clinical effects, therapies, and the ...
Sidney von Niederhausern; Amberly Johnson
core  

Weekly somatrogon vs daily somatropin: a propensity score-matched analysis of growth outcomes from clinical data vs KIGS. [PDF]

J Endocr Soc
Deal CL, Maghnie M, Wang R, Carlsson MO, Wajnrajch MP, Silverman LA, Polak M, La Torre D, Cara JF, Miller BS.   +9 more
europepmc   +1 more source

Disproportionality analysis of sex-stratified adverse event signals in growth impairment: Insights from the FDA adverse event reporting system. [PDF]

Medicine (Baltimore)
Junyu X, Qian C, Jingnan X, Luying Q, Chen Y, Yan Z.   +5 more
europepmc   +1 more source

The efficacy and safety of weekly somatrogon treatment in turkish children with growth hormone deficiency: a real-world cohort study. [PDF]

Endocrine
Gider T, Unal E, Yel S, Kolbaşı B, Düzgün H.   +4 more
europepmc   +1 more source

Treatment with long-acting growth hormone: effectiveness and safety. [PDF]

Front Endocrinol (Lausanne)
Basile L, Cannarella R, Condorelli RA, Frasca F, Calogero AE, La Vignera S.   +5 more
europepmc   +1 more source

Physicochemical Differences Observed in Photostability Studies of Lyophilized, Reconstituted, and Diluted Somatropin. [PDF]

Pharm Res
Pritts JD, Ortega-Rodriguez U, Rao VA.
europepmc   +1 more source

Patient-Centric Design of the Lonapegsomatropin Auto-Injector for Growth Hormone Deficiency: Usability Validation of Safe and Effective Use. [PDF]

Med Devices (Auckl)
Lau M, Fabricius PE, Madsen NB, Egesborg H, Jensen J.   +4 more
europepmc   +1 more source

Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy.

Horm Res Paediatr
Stawerska R, Choe J, Wang R, Wajnrajch MP, Cara JF, Thomas M, La Torre D, Taylor CT, Phillip M, Steelman J, Deal CL, Silverman LA.   +11 more
europepmc   +1 more source